Daily non-political popular news in brief.

Ashkenazi ovarian cancer patients with BRCA mutations live longer than those with normal gene

Israeli investigators have found that Ashkenazi Jewish women with ovarian cancer who have mutations in the BRCA1 or BRCA2 genes lived significantly longer than Ashkenazi Jewish ovarian cancer patients without these mutations. After up to nine years of follow-up, BRCA1/2 mutation carriers were 28 percent less likely to die from the disease, even though women with the BRCA mutations are significantly more likely to develop ovarian and breast cancers.

Read more »

Keywords: ashkenazi, ovarian, cancer, patients, brca, mutations, live, longer, normal, gene, patient, mutation

« Previous | Next »

Similar news on "Ashkenazi ovarian cancer patients with BRCA mutations live longer than those with normal gene":

1. Aggressive therapy best for certain AML patients
   08-01-2007 · EurekAlert!
   A new study suggests that acute leukemia patients whose cancer cells show a genetic change that usually predicts a swift return of the disease following remission may remain disease-free longer when given aggressive therapy. The findings apply to people with acute myeloid leukemia whose cancer cells have normal-looking chromosomes and a gene mutation called MLL-PTD.
   Similar news · Read more »
   
2. Gene thought to assist chemo may help cancer thrive
   05-15-2007 · EurekAlert!
   A gene thought to be essential in helping chemotherapy kill cancer cells, may actually help them thrive. In a new study of chemo patients, scientists at Georgia Tech and the Ovarian Cancer Institute found that 70 percent of subjects whose tumors had mutations in the gene p53 were still alive after five years. Patients with normal p53 displayed only a 30 percent survival rate.
   Similar news · Read more »
   
3. From clinical cancer research: rethinking therapeutic cancer vaccine trials
   07-03-2007 · EurekAlert!
   Ongoing therapeutic cancer vaccine trials have yet to show evidence of vaccines spurring a patient's immune system to shrink tumors -- yet patients who receive these vaccines in trials tend to live longer and respond better to subsequent treatment. In the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, a team of National Cancer Institute researchers asks a fundamental question: are we looking at cancer vaccine trials the wrong way?
   Similar news · Read more »
   
4. Breast cancer gene mutation more common in Hispanic, young black women, Stanford/NCCC study finds
   12-25-2007 · EurekAlert!
   A genetic mutation already known to be more common in Ashkenazi Jewish breast cancer patients is also prevalent in Hispanic and young African-American women with breast cancer, according to one of the largest, multiracial studies of the mutation to date.
   Similar news · Read more »
   
5. Should children be permitted to get genetic testing for BRCA 1/2 mutations?
   01-15-2008 · EurekAlert!
   It's an ethical dilemma with serious implications. Should children be tested for gene mutations that predispose them to developing breast cancer and/or ovarian cancer later in life? New research suggests the next generation of parents may support testing minors even when any steps to reduce that risk will be postponed until adulthood -- a finding that challenges current policies.
   Similar news · Read more »
   
6. Jefferson scientists show gene reverts cancer genes to normal, predicts breast cancer prognosis
   10-31-2006 · EurekAlert!
   Scientists have shown that the activity of a gene that commandeers other cancer-causing genes, returning them to normal, can predict the prognosis of an individual with breast cancer. They looked at cancer cells from more than 2,000 breast cancer patients and found that this commandeering or "organizing" ability is increasingly lost in cancer cells and associated with the progression of disease. The more the gene is expressed in breast cancer, the better the patient did.
   Similar news · Read more »
   
7. Pre-treatment blood test could guide lung cancer therapy
   06-05-2007 · EurekAlert!
   A multi-center team, led by Vanderbilt-Ingram Cancer Center investigators, has developed a new pre-treatment blood test that predicts which non-small-cell lung cancer patients will live longer when they are treated with certain targeted cancer therapies (Iressa, Tarceva). The mass spectrometry-based test, described in the June 6 Journal of the National Cancer Institute, may allow physicians to select the most beneficial therapy for each lung cancer patient, a step forward in the era of personalized medicine.
   Similar news · Read more »
   
8. New study warns against linking ethnic identity to breast cancer genes
   10-26-2006 · EurekAlert!
   Genetic research over the past decade has linked Ashkenazi Jewish ethnicity to an increased risk for hereditary breast cancer, so much so that certain gene mutations have become known as "Jewish ancestral mutations." But a new study released in the November issue of The American Journal of Public Health challenges this approach, warning that disparities in access to care and other unintended consequences can, and have, resulted.
   Similar news · Read more »
   
9. Leading researchers to reveal comprehensive dos and don'ts for prostate cancer
   10-13-2007 · EurekAlert!
   Researchers will share new research on how eating common foods such as tomatoes and fish, maintaining a healthy weight, and avoiding meats cooked at high temperatures may help prevent prostate cancer, and help men live healthier and longer after diagnosis. More widespread studies, in combination with newer technologies in gene research, are substantiating some long-held hypotheses.
   Similar news · Read more »
   
10. Quality of life: most important predictor of survival for advanced NSCLC patients
    10-30-2007 · EurekAlert!
    Healthcare providers have observed it for years -- patients who appear to have a better quality of life while battling their cancer live longer. Now, a prospective, multi-institutional study examining the quality of life of patients with locally advanced non-small cell lung backs that observation. In fact, quality of life is so important, it outweighs other classic predictors of survival.
    Similar news · Read more »